Saad S. Kenderian

Saad S. Kenderian

Auto-generated profile, based on publicly available information

Saad S. Kenderian

Division of Hematology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2019 in Blood
Verified
Journal Article
Open access
PDF file
RSRosalie M. Sterner
Rosalie M. Sterner
RSReona Sakemura
Reona Sakemura
MCMichelle J. Cox
Michelle J. Cox
NYNan Yang
Nan Yang
RKRoman H. Khadka
Roman H. Khadka
SKSaad S. Kenderian
Saad S. Kenderian
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome (CRS) and neurotoxicity. Although the IL-6R antagonist tocilizumab is approved for treatment of CRS, there is no approved treatment of neurotoxicity associated with CD19-targeted CAR-T (CART19) cell therapy. Recent data suggest that monocytes and macrophages contribute to the development of CRS and neurotoxicity after CAR-T cell therapy. Therefore, we investigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential strategy to manage CART19 cell–associated toxicities. In this study, we show that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo. Moreover, CART19 cell proliferation was enhanced and durable control of leukemic disease was maintained better in patient-derived xenografts after GM-CSF neutralization with lenzilumab. In a patient acute lymphoblastic leukemia xenograft model of CRS and neuroinflammation (NI), GM-CSF neutralization resulted in a reduction of myeloid and T cell infiltration in the central nervous system and a significant reduction in NI and prevention of CRS. Finally, we generated GM-CSF–deficient CART19 cells through CRISPR/Cas9 disruption of GM-CSF during CAR-T cell manufacturing. These GM-CSFk/o CAR-T cells maintained normal functions and had enhanced antitumor activity in vivo, as well as improved overall survival, compared with CART19 cells. Together, these studies illuminate a novel approach to abrogate NI and CRS through GM-CSF neutralization, which may potentially enhance CAR-T cell function. Phase 2 studies with lenzilumab in combination with CART19 cell therapy are planned.

29 August 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MRMarco Ruella
Marco Ruella
DBDavid M. Barrett
David M. Barrett
SKSaad S. Kenderian
Saad S. Kenderian
OSOlga Shestova
Olga Shestova
THTed J. Hofmann
Ted J. Hofmann
SGSaar Gill
Saar Gill
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating antigen-loss escapes would therefore represent a vertical advance in the field. Here, we found that in primary patient samples, the IL-3 receptor α chain CD123 was highly expressed on leukemia-initiating cells and CD19-negative blasts in bulk B-ALL at baseline and at relapse after CART19 administration. Using intravital imaging in an antigen-loss CD19-negative relapse xenograft model, we determined that CART123, but not CART19, recognized leukemic blasts, established protracted synapses, and eradicated CD19-negative leukemia, leading to prolonged survival. Furthermore, combining CART19 and CART123 prevented antigen-loss relapses in xenograft models. Finally, we devised a dual CAR-expressing construct that combined CD19- and CD123-mediated T cell activation and demonstrated that it provides superior in vivo activity against B-ALL compared with single-expressing CART or pooled combination CART. In conclusion, these findings indicate that targeting CD19 and CD123 on leukemic blasts represents an effective strategy for treating and preventing antigen-loss relapses occurring after CD19-directed therapies

27 February 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
SKS S Kenderian
S S Kenderian
MRM Ruella
M Ruella
OSO Shestova
O Shestova
MKM Klichinsky
M Klichinsky
VAV Aikawa
V Aikawa
SGS Gill
S Gill

19 March 2022 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
LFLionel A. Kankeu Fonkoua
Lionel A. Kankeu Fonkoua
OSOlivia Sirpilla
Olivia Sirpilla
RSReona Sakemura
Reona Sakemura
ESElizabeth L. Siegler
Elizabeth L. Siegler
SKSaad S. Kenderian
Saad S. Kenderian
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in individuals with hematological malignancies, but its success has been hindered by barriers intrinsic to the tumor microenvironment (TME), particularly for solid tumors, where it has yet to make its mark. In this article, we provide an updated review and future perspectives on features of the TME that represent barriers to CART cell therapy efficacy, including competition for metabolic fuels, physical barriers to infiltration, and immunosuppressive factors. We then discuss novel and promising strategies to overcome these obstacles that are in preclinical development or under clinical investigation.

28 August 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ESElizabeth L. Siegler
Elizabeth L. Siegler
SKSaad S. Kenderian
Saad S. Kenderian
Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.

10 February 2023 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
KCKaran L. Chohan
Karan L. Chohan
ESElizabeth L. Siegler
Elizabeth L. Siegler
SKSaad S. Kenderian
Saad S. Kenderian